These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
262 related articles for article (PubMed ID: 35944147)
1. Enhancing Tumor Therapy of Fe(III)-Shikonin Supramolecular Nanomedicine via Triple Ferroptosis Amplification. Feng W; Shi W; Wang Z; Cui Y; Shao X; Liu S; Rong L; Liu Y; Zhang H ACS Appl Mater Interfaces; 2022 Aug; 14(33):37540-37552. PubMed ID: 35944147 [TBL] [Abstract][Full Text] [Related]
2. Fe(III)-Shikonin Supramolecular Nanomedicine for Combined Therapy of Tumor via Ferroptosis and Necroptosis. Feng W; Shi W; Liu S; Liu H; Liu Y; Ge P; Zhang H Adv Healthc Mater; 2022 Jan; 11(2):e2101926. PubMed ID: 34738742 [TBL] [Abstract][Full Text] [Related]
3. Fe(III)-Shikonin supramolecular nanomedicines as immunogenic cell death stimulants and multifunctional immunoadjuvants for tumor vaccination. Feng W; Shi W; Cui Y; Xu J; Liu S; Gao H; Zhu S; Liu Y; Zhang H Theranostics; 2023; 13(15):5266-5289. PubMed ID: 37908730 [TBL] [Abstract][Full Text] [Related]
4. Degradable iron-rich mesoporous dopamine as a dual-glutathione depletion nanoplatform for photothermal-enhanced ferroptosis and chemodynamic therapy. Cheng H; He Y; Lu J; Yan Z; Song L; Mao Y; Di D; Gao Y; Zhao Q; Wang S J Colloid Interface Sci; 2023 Jun; 639():249-262. PubMed ID: 36805750 [TBL] [Abstract][Full Text] [Related]
5. Potent nanoreactor-mediated ferroptosis-based strategy for the reversal of cancer chemoresistance to Sorafenib. Wang X; Zhao L; Wang C; Wang L; Wu H; Song X; Wang W; Xu H; Dong X Acta Biomater; 2023 Mar; 159():237-246. PubMed ID: 36736851 [TBL] [Abstract][Full Text] [Related]
6. Boosting the Ferroptotic Antitumor Efficacy via Site-Specific Amplification of Tailored Lipid Peroxidation. An Y; Zhu J; Liu F; Deng J; Meng X; Liu G; Wu H; Fan A; Wang Z; Zhao Y ACS Appl Mater Interfaces; 2019 Aug; 11(33):29655-29666. PubMed ID: 31359759 [TBL] [Abstract][Full Text] [Related]
7. Glutathione depletion and dihydroorotate dehydrogenase inhibition actuated ferroptosis-augment to surmount triple-negative breast cancer. Zhou TJ; Zhang MM; Liu DM; Huang LL; Yu HQ; Wang Y; Xing L; Jiang HL Biomaterials; 2024 Mar; 305():122447. PubMed ID: 38154441 [TBL] [Abstract][Full Text] [Related]
8. Synergistic Amplification of Ferroptosis with Liposomal Oxidation Catalyst and Gpx4 Inhibitor for Enhanced Cancer Therapy. Yuan Y; Tian C; Wang Q; Qiu X; Wang Y; Jiang H; Hao J; He Y Adv Healthc Mater; 2023 Nov; 12(28):e2301292. PubMed ID: 37458333 [TBL] [Abstract][Full Text] [Related]
9. Activatable nanomedicine for overcoming hypoxia-induced resistance to chemotherapy and inhibiting tumor growth by inducing collaborative apoptosis and ferroptosis in solid tumors. Fu J; Li T; Yang Y; Jiang L; Wang W; Fu L; Zhu Y; Hao Y Biomaterials; 2021 Jan; 268():120537. PubMed ID: 33260096 [TBL] [Abstract][Full Text] [Related]
10. A tumor microenvironment responsive nanoplatform with oxidative stress amplification for effective MRI-based visual tumor ferroptosis. Luo S; Ma D; Wei R; Yao W; Pang X; Wang Y; Xu X; Wei X; Guo Y; Jiang X; Yuan Y; Yang R Acta Biomater; 2022 Jan; 138():518-527. PubMed ID: 34775124 [TBL] [Abstract][Full Text] [Related]
11. Radiotherapy-mediated redox homeostasis-controllable nanomedicine for enhanced ferroptosis sensitivity in tumor therapy. Lin Y; Chen X; Yu C; Xu G; Nie X; Cheng Y; Luan Y; Song Q Acta Biomater; 2023 Mar; 159():300-311. PubMed ID: 36642338 [TBL] [Abstract][Full Text] [Related]
12. Multienzyme-like Reactivity Cooperatively Impairs Glutathione Peroxidase 4 and Ferroptosis Suppressor Protein 1 Pathways in Triple-Negative Breast Cancer for Sensitized Ferroptosis Therapy. Li K; Lin C; Li M; Xu K; He Y; Mao Y; Lu L; Geng W; Li X; Luo Z; Cai K ACS Nano; 2022 Feb; 16(2):2381-2398. PubMed ID: 35041395 [TBL] [Abstract][Full Text] [Related]
13. NIR-promoted ferrous ion regeneration enhances ferroptosis for glioblastoma treatment. Xue K; Yang R; An Y; Ding Y; Li S; Miao F; Liu D; Chen D; Tang Q J Control Release; 2024 Apr; 368():595-606. PubMed ID: 38185333 [TBL] [Abstract][Full Text] [Related]
14. A Fe(III)-porphyrin-oxaliplatin(IV) nanoplatform for enhanced ferroptosis and combined therapy. Hu X; Li R; Wu W; Fang K; Zhu Z; Wang Y; Zhou L; Chen M; Dong C; Shi S J Control Release; 2022 Aug; 348():660-671. PubMed ID: 35716884 [TBL] [Abstract][Full Text] [Related]
15. Lactic acid responsive sequential production of hydrogen peroxide and consumption of glutathione for enhanced ferroptosis tumor therapy. Zou W; Gao F; Meng Z; Cai X; Chen W; Zheng Y; Ying T; Wang L; Wu J J Colloid Interface Sci; 2024 Jun; 663():787-800. PubMed ID: 38442520 [TBL] [Abstract][Full Text] [Related]
16. pH-Responsive Sorafenib/Iron-Co-Loaded Mesoporous Polydopamine Nanoparticles for Synergistic Ferroptosis and Photothermal Therapy. Liu S; Liu Y; Chang Q; Celia C; Deng X; Xie Y Biomacromolecules; 2024 Jan; 25(1):522-531. PubMed ID: 38087829 [TBL] [Abstract][Full Text] [Related]
17. Multifunctional "ball-rod" Janus nanoparticles boosting Fenton reaction for ferroptosis therapy of non-small cell lung cancer. Zhu G; Chi H; Liu M; Yin Y; Diao H; Liu Z; Guo Z; Xu W; Xu J; Cui C; Xing XJ; Ma K J Colloid Interface Sci; 2022 Sep; 621():12-23. PubMed ID: 35447518 [TBL] [Abstract][Full Text] [Related]
18. Cyclodextrin-Derived ROS-Generating Nanomedicine with pH-Modulated Degradability to Enhance Tumor Ferroptosis Therapy and Chemotherapy. Xu M; Zha H; Han R; Cheng Y; Chen J; Yue L; Wang R; Zheng Y Small; 2022 May; 18(20):e2200330. PubMed ID: 35451223 [TBL] [Abstract][Full Text] [Related]
19. Fe(III)-Naphthazarin Metal-Phenolic Networks for Glutathione-Depleting Enhanced Ferroptosis-Apoptosis Combined Cancer Therapy. Liu Z; Liu S; Liu B; Bian Y; Yuan M; Yang C; Meng Q; Chen C; Ma P; Lin J Small; 2023 May; 19(19):e2207825. PubMed ID: 36772903 [TBL] [Abstract][Full Text] [Related]
20. Dual-Responsive multifunctional "core-shell" magnetic nanoparticles promoting Fenton reaction for tumor ferroptosis therapy. Chi H; Zhu G; Yin Y; Diao H; Liu Z; Sun S; Guo Z; Xu W; Xu J; Cui C; Xing XJ; Ma K Int J Pharm; 2022 Jun; 622():121898. PubMed ID: 35688287 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]